Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 49

    1.

    CA-125 can be part of the tumour evaluation criteria in ovarian cancer trials: experience of the GCIG CALYPSO trial.

    Alexandre J, Brown C, Coeffic D, Raban N, Pfisterer J, Mäenpää J, Chalchal H, Fitzharris B, Volgger B, Vergote I, Pisano C, Ferrero A, Pujade-Lauraine E.

    Br J Cancer. 2012 Feb 14;106(4):633-7. doi: 10.1038/bjc.2011.593. Epub 2012 Jan 12.

    PMID:
    22240800
    [PubMed - indexed for MEDLINE]
    2.

    The cyclin-dependent kinase inhibitor p57(Kip2) is epigenetically regulated in carboplatin resistance and results in collateral sensitivity to the CDK inhibitor seliciclib in ovarian cancer.

    Coley HM, Safuwan NA, Chivers P, Papacharalbous E, Giannopoulos T, Butler-Manuel S, Madhuri K, Lovell DP, Crook T.

    Br J Cancer. 2012 Jan 31;106(3):482-9. doi: 10.1038/bjc.2011.566. Epub 2012 Jan 10.

    PMID:
    22233925
    [PubMed - indexed for MEDLINE]
    3.

    Dietary fat intake and risk of ovarian cancer in the NIH-AARP Diet and Health Study.

    Blank MM, Wentzensen N, Murphy MA, Hollenbeck A, Park Y.

    Br J Cancer. 2012 Jan 31;106(3):596-602. doi: 10.1038/bjc.2011.572. Epub 2012 Jan 5.

    PMID:
    22223086
    [PubMed - indexed for MEDLINE]
    4.

    Indole-3-carbinol synergistically sensitises ovarian cancer cells to bortezomib treatment.

    Taylor-Harding B, Agadjanian H, Nassanian H, Kwon S, Guo X, Miller C, Karlan BY, Orsulic S, Walsh CS.

    Br J Cancer. 2012 Jan 17;106(2):333-43. doi: 10.1038/bjc.2011.546. Epub 2011 Dec 13.

    PMID:
    22166800
    [PubMed - indexed for MEDLINE]
    5.

    15. Cancers attributable to reproductive factors in the UK in 2010.

    Parkin DM.

    Br J Cancer. 2011 Dec 6;105 Suppl 2:S73-6. doi: 10.1038/bjc.2011.488. No abstract available.

    PMID:
    22158326
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    6.

    10. Cancers attributable to exposure to hormones in the UK in 2010.

    Parkin DM.

    Br J Cancer. 2011 Dec 6;105 Suppl 2:S42-8. doi: 10.1038/bjc.2011.483. No abstract available.

    PMID:
    22158320
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    7.

    Elevated mRNA expression of CHAC1 splicing variants is associated with poor outcome for breast and ovarian cancer patients.

    Goebel G, Berger R, Strasak AM, Egle D, Müller-Holzner E, Schmidt S, Rainer J, Presul E, Parson W, Lang S, Jones A, Widschwendter M, Fiegl H.

    Br J Cancer. 2012 Jan 3;106(1):189-98. doi: 10.1038/bjc.2011.510. Epub 2011 Nov 22.

    PMID:
    22108517
    [PubMed - indexed for MEDLINE]
    8.

    Phase I/II study of sagopilone (ZK-EPO) plus carboplatin in women with recurrent platinum-sensitive ovarian cancer.

    McMeekin S, Patel R, Verschraegen C, Celano P, Burke J 2nd, Plaxe S, Ghatage P, Giurescu M, Stredder C, Wang Y, Schmelter T.

    Br J Cancer. 2012 Jan 3;106(1):70-6. doi: 10.1038/bjc.2011.499. Epub 2011 Nov 22.

    PMID:
    22108514
    [PubMed - indexed for MEDLINE]
    9.

    Δ133p53 is an independent prognostic marker in p53 mutant advanced serous ovarian cancer.

    Hofstetter G, Berger A, Schuster E, Wolf A, Hager G, Vergote I, Cadron I, Sehouli J, Braicu EI, Mahner S, Speiser P, Marth C, Zeimet AG, Ulmer H, Zeillinger R, Concin N.

    Br J Cancer. 2011 Nov 8;105(10):1593-9. doi: 10.1038/bjc.2011.433. Epub 2011 Oct 18.

    PMID:
    22009029
    [PubMed - indexed for MEDLINE]
    10.

    Long-term survival of young women receiving fertility-sparing surgery for ovarian cancer in comparison with those undergoing radical surgery.

    Kajiyama H, Shibata K, Mizuno M, Umezu T, Suzuki S, Nawa A, Kawai M, Nagasaka T, Kikkawa F.

    Br J Cancer. 2011 Oct 25;105(9):1288-94. doi: 10.1038/bjc.2011.394. Epub 2011 Oct 4.

    PMID:
    21970882
    [PubMed - indexed for MEDLINE]
    11.

    Prognostic nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancer.

    Lee CK, Simes RJ, Brown C, Lord S, Wagner U, Plante M, Vergote I, Pisano C, Parma G, Burges A, Bourgeois H, Högberg T, Bentley J, Angleitner-Boubenizek L, Ferrero A, Richter B, Hirte H, Gebski V, Pfisterer J, Pujade-Lauraine E, Friedlander M.

    Br J Cancer. 2011 Oct 11;105(8):1144-50. doi: 10.1038/bjc.2011.364. Epub 2011 Sep 13.

    PMID:
    21915127
    [PubMed - indexed for MEDLINE]
    12.

    Oral contraceptive use and reproductive factors and risk of ovarian cancer in the European Prospective Investigation into Cancer and Nutrition.

    Tsilidis KK, Allen NE, Key TJ, Dossus L, Lukanova A, Bakken K, Lund E, Fournier A, Overvad K, Hansen L, Tjønneland A, Fedirko V, Rinaldi S, Romieu I, Clavel-Chapelon F, Engel P, Kaaks R, Schütze M, Steffen A, Bamia C, Trichopoulou A, Zylis D, Masala G, Pala V, Galasso R, Tumino R, Sacerdote C, Bueno-de-Mesquita HB, van Duijnhoven FJ, Braem MG, Onland-Moret NC, Gram IT, Rodríguez L, Travier N, Sánchez MJ, Huerta JM, Ardanaz E, Larrañaga N, Jirström K, Manjer J, Idahl A, Ohlson N, Khaw KT, Wareham N, Mouw T, Norat T, Riboli E.

    Br J Cancer. 2011 Oct 25;105(9):1436-42. doi: 10.1038/bjc.2011.371. Epub 2011 Sep 13.

    PMID:
    21915124
    [PubMed - indexed for MEDLINE]
    13.

    Prognostic role of CIP2A expression in serous ovarian cancer.

    Böckelman C, Lassus H, Hemmes A, Leminen A, Westermarck J, Haglund C, Bützow R, Ristimäki A.

    Br J Cancer. 2011 Sep 27;105(7):989-95. doi: 10.1038/bjc.2011.346. Epub 2011 Sep 6.

    PMID:
    21897396
    [PubMed - indexed for MEDLINE]
    14.

    Initial toxicity assessment of ICON6: a randomised trial of cediranib plus chemotherapy in platinum-sensitive relapsed ovarian cancer.

    Raja FA, Griffin CL, Qian W, Hirte H, Parmar MK, Swart AM, Ledermann JA.

    Br J Cancer. 2011 Sep 27;105(7):884-9. doi: 10.1038/bjc.2011.334. Epub 2011 Aug 30.

    PMID:
    21878941
    [PubMed - indexed for MEDLINE]
    15.

    Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort.

    Zang RY, Harter P, Chi DS, Sehouli J, Jiang R, Tropé CG, Ayhan A, Cormio G, Xing Y, Wollschlaeger KM, Braicu EI, Rabbitt CA, Oksefjell H, Tian WJ, Fotopoulou C, Pfisterer J, du Bois A, Berek JS.

    Br J Cancer. 2011 Sep 27;105(7):890-6. doi: 10.1038/bjc.2011.328. Epub 2011 Aug 30.

    PMID:
    21878937
    [PubMed - indexed for MEDLINE]
    16.

    Trends in breast, ovarian and cervical cancer incidence in Mumbai, India over a 30-year period, 1976-2005: an age-period-cohort analysis.

    Dhillon PK, Yeole BB, Dikshit R, Kurkure AP, Bray F.

    Br J Cancer. 2011 Aug 23;105(5):723-30. doi: 10.1038/bjc.2011.301. Epub 2011 Aug 9.

    PMID:
    21829198
    [PubMed - indexed for MEDLINE]
    17.

    Prognostic impact of lymphadenectomy in clinically early stage malignant germ cell tumour of the ovary.

    Mahdi H, Swensen RE, Hanna R, Kumar S, Ali-Fehmi R, Semaan A, Tamimi H, Morris RT, Munkarah AR.

    Br J Cancer. 2011 Aug 9;105(4):493-7. doi: 10.1038/bjc.2011.267. Epub 2011 Jul 19.

    PMID:
    21772335
    [PubMed - indexed for MEDLINE]
    18.

    Carboplatin-paclitaxel-induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian cancer.

    Lee CK, Gurney H, Brown C, Sorio R, Donadello N, Tulunay G, Meier W, Bacon M, Maenpaa J, Petru E, Reed N, Gebski V, Pujade-Lauraine E, Lord S, Simes RJ, Friedlander M.

    Br J Cancer. 2011 Jul 26;105(3):360-5. doi: 10.1038/bjc.2011.256. Epub 2011 Jul 12.

    PMID:
    21750553
    [PubMed - indexed for MEDLINE]
    19.

    Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines.

    Peasland A, Wang LZ, Rowling E, Kyle S, Chen T, Hopkins A, Cliby WA, Sarkaria J, Beale G, Edmondson RJ, Curtin NJ.

    Br J Cancer. 2011 Jul 26;105(3):372-81. doi: 10.1038/bjc.2011.243. Epub 2011 Jul 5.

    PMID:
    21730979
    [PubMed - indexed for MEDLINE]
    20.

    The performance of the risk of ovarian malignancy algorithm.

    Langmár Z, Németh M, Székely B, Borgulya G.

    Br J Cancer. 2011 Jun 28;105(1):185-6; author reply 187-8. doi: 10.1038/bjc.2011.224. No abstract available.

    PMID:
    21712847
    [PubMed - indexed for MEDLINE]

      Display Settings:

      Format
      Items per page
      Sort by

      Send to:

      Choose Destination

      Supplemental Content

      Find related data

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk